Drug intelligence / Profile preview

LY4292009

Development stage: Phase 1
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY4292009 (also known as MORF-440) is an orally available integrin modulator under development for therapeutic indications. It is being developed by Morphic Holdings, a subsidiary of Eli Lilly, and is currently undergoing Phase 1 clinical evaluation to assess the safety and tolerability of single ascending doses in healthy participants. As of July 2025, its precise mechanism of action and target indications have not been publicly detailed, but it is characterized broadly as an integrin modulator, suggesting it acts on integrin proteins, which play roles in cell adhesion and signal transduction[5][1][7].

Other names: MORF-440MORF440MORF 440

Beyond the preview

Go deeper on LY4292009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY4292009.

Explore the full profile